Elypta is a diagnostics firm pioneering metabolism-based liquid biopsies. Its technology allows for non-invasive, safe, and cost-effective tests needed for early cancer diagnoses and for patients’ continued monitoring. Starting with kidney cancer, Elypta’s technology is being developed to ultimately be validated across multiple cancers.